REDUCED PREDNISOLONE BIOAVAILABILITY DURING RIFAMPICIN TREATMENT

被引：0

作者：

BERGREM, H ^{[1
]}

REFVEM, OK ^{[1
]}

机构：

[1] NATL UNIV HOSP OSLO,RIKSHOSP,MED DEPT B,OSLO,NORWAY

来源：

KIDNEY INTERNATIONAL | 1983年 / 23卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：551 / 551

页数：1

共 50 条

[21] DRUG-COMBINATIONS AND THE BIOAVAILABILITY OF RIFAMPICIN
ACOCELLA, G
TUBERCLE AND LUNG DISEASE, 1992, 73 (04): : 242 - 244
[22] RIFAMPICIN REDUCES BIOAVAILABILITY OF CHLORAMPHENICOL AND VERAPAMIL
DARCY, PF
PHARMACY INTERNATIONAL, 1985, 6 (07): : 149 - 150
[23] DRUG-COMBINATIONS AND THE BIOAVAILABILITY OF RIFAMPICIN
FOX, W
TUBERCLE, 1990, 71 (04): : 241 - 245
[24] Buccal films of prednisolone with enhanced bioavailability
Kumria, Rachna
Nair, Anroop B.
Goomber, Garima
Gupta, Sumeet
DRUG DELIVERY, 2016, 23 (02) : 471 - 478
[25] DOES CHOLESTYRAMINE IMPAIR BIOAVAILABILITY OF PREDNISOLONE
AUDETAT, V
PAUMGARTNER, G
BIRCHER, J
SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1977, 107 (15) : 527 - 528
[26] OCULAR BIOAVAILABILITY OF TOPICAL PREDNISOLONE PREPARATIONS
OLEJNIK, O
WEISBECKER, CA
CLINICAL THERAPEUTICS, 1990, 12 (01) : 2 - 11
[27] RELATIVE BIOAVAILABILITY OF PREDNISONE AND PREDNISOLONE IN MAN
TSE, FLS
WELLING, PG
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1979, 31 (07) : 492 - 493
[28] CHOLESTATIC HEPATITIS DURING TREATMENT WITH INH AND RIFAMPICIN - ARGUMENTS IN FAVOR OF THE HEPATOTOXICITY OF RIFAMPICIN
POUPON, RY
MEYNIEL, D
PETIT, J
GUSTOT, P
DARNIS, F
ANNALES DE MEDECINE INTERNE, 1979, 130 (6-7): : 371 - 375
[29] Novel anti-tuberculosis FDC formulations without reduced bioavailability of rifampicin: from concept to market
Singh, S
Mariappan, TT
Bhutani, H
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2005, 9 (06) : 701 - 702
[30] SEVERE ADVERSE REACTION DURING TREATMENT WITH RIFAMPICIN
EBRI, B
ARINO, MD
CABEZA, F
SEBASTIAN, A
REVISTA CLINICA ESPANOLA, 1992, 191 (04): : 231 - 232

← 1 2 3 4 5 →